Multiple Sclerosis, Secondary Progressive Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Multiple Sclerosis, Secondary Progressive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Stanford University12 enrolled1 locationNCT06138132
Recruiting
Not Applicable

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab22 enrolled1 locationNCT06390930
Recruiting

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive+1 more
University Hospital, Basel, Switzerland100 enrolled1 locationNCT06526364
Recruiting
Not Applicable

Intermittent Hypoxia in Persons With Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab21 enrolled1 locationNCT06276634
Recruiting

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive+1 more
Shirley Ryan AbilityLab40 enrolled1 locationNCT06516458
Recruiting

MS-ResearchBiomarkerS

Neurologic DisorderMultiple SclerosisClinically Isolated Syndrome+8 more
Cedars-Sinai Medical Center1,000 enrolled1 locationNCT05204459
Recruiting
Phase 2Phase 3

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Multiple SclerosisMultiple Sclerosis, Secondary Progressive
Institute of Psychiatry and Neurology, Warsaw188 enrolled1 locationNCT05961644